Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders
Chronic kidney disease
Diabetes devices & technology
GLP-1 receptor agonists
Hyperglycemia
Hypoglycemia
Obesity, diet, & lifestyle interventions
SGLT2 inhibitors
Type 1 diabetes
Type 2 diabetes
Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring
Fasting for religion and health in people with diabetes
The challenge of type 2 diabetes in children
HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved
Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice
The SURPASS trials: Summarizing efficacy data on tirzepatide
Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials
Why psychosocial care matters
DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022
The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Log in

SGLT2 inhibitors


Browse the latest news, expert commentary, and educational content on the SGLT2 inhibitor medication class.


Highlights

12-09-2022 | Medications | News

TriMaster data support ‘try before you choose’ for type 2 diabetes medications

Allowing people to try out medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication, say the TriMaster investigators.

12-05-2022 | SGLT2 inhibitors | News

Algorithm could optimize SGLT2 vs DPP-4 inhibitor decisions in clinical practice

An algorithm based on real-world clinical data could support decisions between use of SGLT2 inhibitors and DPP-4 inhibitors in people with type 2 diabetes.

11-18-2022 | Dapagliflozin | News

Dapagliflozin HFpEF benefits independent of glucose levels

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.

SGLT2 inhibitors and finerenone for kidney disease treatment

Ian de Boer joins Amrit Lamba to discuss how these medications will influence the treatment of kidney disease in people with DKD.

10-24-2022 | Cardiovascular outcomes | News

Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection

10-06-2022 | SGLT2 inhibitors | News

SGLT2 inhibitors linked to lower gout risk than DPP-4 inhibitors

09-02-2022 | Dapagliflozin | News

DELIVER results round-up: Frailty, AF, recent hospitalization, and more

08-27-2022 | Dapagliflozin | News

Dapagliflozin DELIVERs improved HFpEF outcomes

08-25-2022 | Physical activity | News

Initiating glucose-lowering therapy may be linked to a reduction in physical activity

08-18-2022 | Finerenone | News

Finerenone benefits independent of SGLT2 inhibitor use

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Sign up for the e-alert today

SGLT2 inhibitor use in type 2 diabetes management

Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.
  • » A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
  • » SGLT2 inhibitors: Key evidence and implications for clinical practice
  • » Translating SGLT2 inhibitor cardiovascular evidence into practice
  • » This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.
Image Credits